阿替普酶溶栓治疗心源性脑梗死后血清BNP、HGF和S-100β蛋白的变化

发布时间：2018-05-18 08:49

本文选题：心源性脑梗死 + 阿替普酶　；参考：《中国老年学杂志》2017年24期

【摘要】：目的探讨阿替普酶(rt-PA)溶栓治疗心源性脑梗死后血清脑钠肽(BNP)、肝细胞生长因子(HGF)和S-100β蛋白的表达水平及临床意义。方法心源性脑梗死患者120例,按照美国国立卫生研究院卒中量表(NIHSS)评分分为轻型、中型和重型脑梗死;按照脑梗死体积分为小、中和大梗死灶组。比较不同程度脑梗死患者和不同梗死体积患者血清BNP、HGF和S-100β蛋白水平的差异。随机将患者分为rt-PA静脉溶栓治疗组(60例)和非溶栓治疗对照组(60例),治疗前及治疗1、3、7 d时统计两组NIHSS评分、治疗效果,检测不同治疗时间点血清BNP、HGF和S-100β蛋白水平的变化。结果随着脑梗死程度加重和脑梗死体积的增加,血清BNP、HGF和S-100β蛋白水平均逐渐升高(P0.05)。治疗后1、3、7 d,治疗组NIHSS评分均显著低于对照组(P0.05);治疗组总有效率显著高于对照组(P0.05);随着治疗时间的延长,治疗组血清BNP、HGF和S-100β蛋白水平均显著低于治疗前(P0.05);且对照组只在第7天检测时显著低于治疗前(P0.05);同一检测时间点,治疗组均显著低于对照组(P0.05)。结论阿替普酶溶栓治疗心源性脑梗死具有较好的治疗效果,血清BNP、HGF和S-100β蛋白水平与心源性脑梗死病情严重程度和梗死体积呈正相关关系,对于心源性脑梗死的临床诊断、病情监测和疗效评价具有重要的意义。
[Abstract]:Objective to investigate the expression levels of BNP, HGFand S-100 尾 protein and S-100 尾 protein in patients with cardiogenic cerebral infarction after thrombolytic therapy. Methods 120 patients with cardiogenic cerebral infarction were divided into mild moderate and severe cerebral infarction according to the National Institutes of Health Stroke scale (NIHSS) and small moderate and large infarct according to the volume of cerebral infarction. The serum BNPHGF and S-100 尾 protein levels were compared between patients with different degrees of cerebral infarction and patients with different infarct volumes. The patients were randomly divided into rt-PA intravenous thrombolytic therapy group (n = 60) and non-thrombolytic therapy group (n = 60). The NIHSS scores of the two groups were calculated before treatment and 1 day after treatment. The effect of treatment and the changes of serum BNP-HGF and S-100 尾 protein were detected at different time points. Results with the aggravation of cerebral infarction and the increase of cerebral infarction volume, the levels of serum BNPP HGF and S-100 尾 protein increased gradually (P 0.05). The NIHSS scores in the treatment group were significantly lower than those in the control group at 1: 3 and 7 days after treatment, and the total effective rate in the treatment group was significantly higher than that in the control group, and with the prolongation of the treatment time, the total effective rate of the treatment group was significantly higher than that of the control group. The levels of serum BNPP HGF and S-100 尾 protein in the treatment group were significantly lower than those in the control group before treatment, and in the control group were only significantly lower than that in the control group on the 7th day, and at the same time point, the levels of BNPHGF and S-100 尾 protein in the treatment group were significantly lower than those in the control group. Conclusion Atiplase thrombolytic therapy is effective in the treatment of cardiogenic cerebral infarction. The levels of serum BNPP HGF and S-100 尾 protein are positively correlated with the severity of cardiogenic cerebral infarction and the volume of infarction, and the clinical diagnosis of cardiogenic cerebral infarction. It is of great significance to monitor the disease and evaluate the curative effect.
【作者单位】：武汉市武昌医院神经内科;
【基金】：湖北省卫计委资助项目(WJ2015MB250) 武汉市卫计委资助项目(WX15C17)
【分类号】：R743.33

【相似文献】